Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

943 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Disease-associated astrocyte epigenetic memory promotes CNS pathology.
Lee HG, Rone JM, Li Z, Akl CF, Shin SW, Lee JH, Flausino LE, Pernin F, Chao CC, Kleemann KL, Srun L, Illouz T, Giovannoni F, Charabati M, Sanmarco LM, Kenison JE, Piester G, Zandee SEJ, Antel J, Rothhammer V, Wheeler MA, Prat A, Clark IC, Quintana FJ. Lee HG, et al. Among authors: prat a. bioRxiv [Preprint]. 2024 Jan 5:2024.01.04.574196. doi: 10.1101/2024.01.04.574196. bioRxiv. 2024. Update in: Nature. 2024 Mar;627(8005):865-872. doi: 10.1038/s41586-024-07187-5 PMID: 38260616 Free PMC article. Updated. Preprint.
Gaining Biological Insights through Supervised Data Visualization.
Rhodes JS, Aumon A, Morin S, Girard M, Larochelle C, Brunet-Ratnasingham E, Pagliuzza A, Marchitto L, Zhang W, Cutler A, Grand'Maison F, Zhou A, Finzi A, Chomont N, Kaufmann DE, Zandee S, Prat A, Wolf G, Moon KR. Rhodes JS, et al. Among authors: prat a. bioRxiv [Preprint]. 2024 Jan 21:2023.11.22.568384. doi: 10.1101/2023.11.22.568384. bioRxiv. 2024. PMID: 38293135 Free PMC article. Preprint.
HER2DX genomic test in early-stage HER2-positive breast cancer.
Tolaney SM, Tung N, Wolff AC, DeMichele A, Cejalvo JM, Martínez-Sáez O, Pascual T, Waks AG, Martín M, Ciruelos E, Harbeck N, Carey LA, Cortés J, Curigliano G, Prat A. Tolaney SM, et al. Among authors: prat a. ESMO Open. 2024 Dec;9(12):103987. doi: 10.1016/j.esmoop.2024.103987. Epub 2024 Nov 16. ESMO Open. 2024. PMID: 39710442 Free PMC article. Review.
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis.
Schettini F, Nucera S, Pascual T, Martínez-Sáez O, Sánchez-Bayona R, Conte B, Buono G, Lambertini M, Punie K, Cejalvo JM, Arpino G, Vigneri P, Generali D, Ciruelos E, Cortés J, Gennari A, Muñoz M, Vidal Losada MJ, Tolaney SM, Prat A, Villacampa G. Schettini F, et al. Among authors: prat a. Cancer Treat Rev. 2024 Dec 19;132:102865. doi: 10.1016/j.ctrv.2024.102865. Online ahead of print. Cancer Treat Rev. 2024. PMID: 39709655 Free article. Review.
Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2+ early breast cancer (EBC).
Fernandez-Martinez A, Tanioka M, Ahn SG, Zagami P, Pascual T, Rediti M, Tang G, Hoadley KA, Venet D, Rashid NU, Spears PA, Di Cosimo S, de Azambuja E, Choudhury A, Rastogi P, Islam MN, Cortes J, Llombart-Cussac A, Swain SM, Sotiriou C, Prat A, Perou CM, Carey LA. Fernandez-Martinez A, et al. Among authors: prat a. Ann Oncol. 2024 Dec 18:S0923-7534(24)04989-5. doi: 10.1016/j.annonc.2024.12.010. Online ahead of print. Ann Oncol. 2024. PMID: 39706338 Free article.
Widespread gene-environment interactions shape the immune response to SARS-CoV-2 infection in hospitalized COVID-19 patients.
Randolph HE, Aguirre-Gamboa R, Brunet-Ratnasingham E, Nakanishi T, Locher V, Ketter E, Brandolino C, Larochelle C, Prat A, Arbour N, Dumaine A, Finzi A, Durand M, Richards JB, Kaufmann DE, Barreiro LB. Randolph HE, et al. Among authors: prat a. bioRxiv [Preprint]. 2024 Dec 4:2024.12.03.626676. doi: 10.1101/2024.12.03.626676. bioRxiv. 2024. PMID: 39677792 Free PMC article. Preprint.
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network.
Lorscheider J, Signori A, Subramaniam S, Benkert P, Vukusic S, Trojano M, Hillert J, Glaser A, Hyde R, Spelman T, Magyari M, Elberling F, Pontieri L, Koch-Henriksen N, Sørensen PS, Gerlach O, Prat A, Girard M, Eichau S, Grammond P, Horakova D, Ramo-Tello C, Roos I, Buzzard K, Lechner Scott J, Sánchez-Menoyo JL, Alroughani R, Prévost J, Kuhle J, Gray O, Mathey G, Michel L, Ciron J, De Sèze J, Maillart E, Ruet A, Labauge P, Zephir H, Kwiatkowski A, van der Walt A, Kalincik T, Butzkueven H; Italian MS Register; Observatoire Français de la Sclérose en Plaques (OFSEP); MSBase Study Group; Swedish MS Registry; Big MS Data Network. Lorscheider J, et al. Among authors: prat a. J Neurol Neurosurg Psychiatry. 2024 Dec 6:jnnp-2024-334700. doi: 10.1136/jnnp-2024-334700. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 39643429 Free article.
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, Park YH, Prat A, Bachelot T, Juric D, Turner N, Sophos N, Zarate JP, Arce C, Shen YM, Turner S, Kanakamedala H, Hsu WC, Chia S. Rugo HS, et al. Among authors: prat a. Lancet Oncol. 2024 Dec;25(12):e629-e638. doi: 10.1016/S1470-2045(24)00673-9. Lancet Oncol. 2024. PMID: 39637900 Clinical Trial.
Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study.
Schettini F, Brasó-Maristany F, Pascual T, Lorman-Carbó N, Nucera S, Bergamino M, Galván P, Conte B, Seguí E, García Fructuoso I, Gómez Bravo R, Rodríguez AB, Martínez-Sáez O, Chic N, Vidal M, Adamo B, González-Farre B, Sanfeliu E, Cebrecos I, Mensión E, Oses G, Locci M, Mollà M, Ganau S, Jares P, Vidal-Sicart S, Muñoz M, Prat A. Schettini F, et al. Among authors: prat a. ESMO Open. 2024 Dec;9(12):103989. doi: 10.1016/j.esmoop.2024.103989. Epub 2024 Nov 27. ESMO Open. 2024. PMID: 39608304 Free PMC article.
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy.
Pernas S, Sanfeliu E, Villacampa G, Salvador J, Perelló A, González X, Jiménez B, Merino M, Palacios P, Pascual T, Alba E, Villanueva L, Chillara S, Ferrero-Cafiero JM, Galvan P, Prat A, Ciruelos E. Pernas S, et al. Among authors: prat a. NPJ Breast Cancer. 2024 Nov 26;10(1):101. doi: 10.1038/s41523-024-00710-x. NPJ Breast Cancer. 2024. PMID: 39592624 Free PMC article.
943 results